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SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comdecreased at 1M after renal denervation procedure. NT-proBNP (126; 87-178 at 1M
vs. 353; 178-490 at B, p< 0.01), NE (441; 198-598 at 1M vs. 752; 629-850 at B, p<
0.01) and A (98; 75-128 at 1M vs. 165; 114-269 at B, p< 0.01) all decreased at 1M
after renal denervation procedure, while PRA did not change. Percentual decrease of
mean arterial pressure was strictly correlated with both percentual decrease in NT-
proBNP (r¼ 0.742, p< 0.05) and NE (r¼ 0.924, p< 0.01).
Conclusions: Biomarkers of neurohormonal activation and cardiovascular overload
such as norepinephrine, aldosterone and B-type natriuretic peptides appear positively
affected by renal denervation procedure in resistant hypertensive patients. Interest-
ingly, decrease of such neurohormones strictly reﬂect decrease in arterial pressure
values.
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Background: Renal denervation for refractory hypertension has received considerable
interest in recent years. Initial clinical data demonstrated a signiﬁcant reduction in
blood pressure following radiofrequency ablation of the renal nerves. However, the
recent clinical trial SYMPLICITY HTN-3 failed to meet efﬁcacy endpoints. One
theory for insufﬁcient efﬁcacy is incomplete ablation of the renal nerve. In this study
we test if the renal nerves, in particular the main renal nerve bundle, could be visu-
alized through the renal arterial wall using optical coherence tomography (OCT) to
guide more precise ablative energy.
Methods: Specimens included fresh porcine abdominal aortas with kidneys attached.
The Ocelot catheter (Avinger Inc, Redwood City, CA) using a 1300 nm OCT swept
source laser was inserted through the aorta and advanced to the renal artery. Following
OCT imaging, the tissue was ﬁxed, sectioned (5 mm thick), and stained with hema-
toxylin and eosin.
Results: Figure 1 displays an OCT image from within the renal artery juxtaposed with
the identical histologic arterial section. OCT accurately identiﬁes the location of the
renal nerve bundle via the optical properties of the surrounding myelin, which creates
delineated borders when compared with neighboring adventitia.
Conclusions: OCT is gaining increased use within cardiovascular imaging and
therapy. The clear identiﬁcation and localization of the renal nerve bundle via OCT
may prove useful for targeted ablative therapies, including renal denervation.B124 JACC Vol 64/11/Suppl B j September 13–17, 2014TCT-423
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Background: While the efﬁcacy of a ﬁrst generation radio frequency renal dener-
vation device has recently been challenged, new technologies are available designed
to optimize procedural success. The Paradise Renal Denervation System (ReCor
Medical, Palo Alto, CA) delivers ultrasound energy to perform targeted circumfer-
ential denervation of the renal sympathetic nerves in order to reduce blood pressure
(BP) and secondary end-organ damage.
Methods: The ACHIEVE study is a prospective, multi-center, non-randomized,
post-market study to evaluate the clinical outcome of renal denervation with the
Paradise System in patients with resistant hypertension. Major exclusions include
renal artery stenosis and moderate to severe renal insufﬁciency. Patients were
treated with the Paradise system and followed for 12 months. Non-invasive im-
aging using CR or MRI was performed at 12-months to assess renal artery patency.
Safety and efﬁcacy endpoints were evaluated including renal complications,
changes in ofﬁce and ambulatory BP, changes in medication and Quality of Life
measures.
Results: Eight sites in Europe are actively recruiting in the ACHIEVE study.
Mean age at treatment is 6311 years (range 38-86 years) and 56% of patients
are male. At baseline, mean ofﬁce systolic BP is 17720 mmHg (n¼67) and
mean ambulatory systolic BP is 15613 mmHg (n¼62). Early data demonstrate a
signiﬁcant decrease in systolic ofﬁce BP at 30 days post treatment (average BP
change of -16mmHg, n¼47, p< 0.005), sustained at both 3 and 6 months. Pa-
tients with baseline ofﬁce BP 160mmHg had larger overall drops in systolic BP
versus those whose baseline BP was < 160mmHg (-1929mmHg; n¼29; p<
0.005 versus 2.120mmHg, n¼8). Average 24-hour ambulatory blood pressure
changes are also sustained over follow-up with an average decrease of -7mmHg
recorded at both 3 and 6 months post treatment. No procedure related serious
adverse events occurred in the initial follow-up. Updated results will be presented
at the meeting.
Conclusions: Initial ACHIEVE study results demonstrate that the Paradise System is
safe and effective in patients with resistant hypertension. Early data suggests that a
reduction in BP occurs within 30 days and is sustained.
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Background: Catheter-based renal sympathetic denervation (RDN) is indicated for
treatment-resistant arterial hypertension (systolic pressure 160 mmHg on 3 anti-
hypertensive drugs). A radiofrequency catheter induces controlled thermal sympa-
thetic nerve destruction in the renal arteries resulting in lowered sympathetic tone and
blood pressure (BP). According to the Symplicity trials, patients with anatomical
abnormalities of the renal arteries like additional arteries or early bifurcations have not
been eligible for this treatment.
Methods: Our study carefully investigated the ambulatory 24 hour blood pressure
(ABPM) response to RDN in a cohort of 181 consecutively treated patients with
resistant hypertension. A 24h BP monitoring was recorded in every patient 24h
before as well as 24h, 3 and 6 months after RDN. According to the renal artery
anatomical ﬁndings, the following 5 groups have been identiﬁed: normal anat-
omy, additional arteries, early bifurcation (segmental bifurcation < 15mm from
the ostium), tortuosity and atherosclerotic plaque. All data were statistically
analysed with repeated measures ANOVA and Greenhouse-Geisser correction if
indicated.
Results: In treated patients (age 63 9.6 years, BMI 31.9 5.8 Kg/m2, 48% women,
48% diabetic, 19% coronary artery disease and 5.7 1.8 antihypertensive medica-
tions) mean averaged systolic 24h BP was signiﬁcantly reduced in every anatomical
group during the ﬁrst 24 hours. Patients with additional renal arteries or early bi-
furcations seem to have a more sustained systolic BP reduction at 3 and 6 months
compared to tortuous renal arteries, evidence of plaque or normal anatomies. Here a
relapse to baseline BP was seen.
Conclusions: Patients with resistant hypertension and unfavourable renal vascular
anatomy seem to beneﬁt at least to an equal extent from RDN as patients with normal
renal arteries. However, our data suggest, that tortuosity and atherosclerotic plaque
may be a negative predictor of BP response, whereas early bifurcations and additional
renal arteries appear to be positive predictors.j TCT Abstracts/Hypertension Therapies Including Renal Denervation
